ZNF446 is a KRAB-containing zinc finger transcription factor involved in transcriptional regulation. Structurally, it contains a KRAB repressor domain and three C(2)H(2) zinc fingers, with expression across multiple human tissues including particularly high levels in muscle 1. As a transcriptional repressor, ZNF446 inhibits serum response factor (SRE) and AP-1 activities, suggesting a role in regulating mitogen-activated protein kinase (MAPK) signaling pathways 1. Disease relevance spans multiple systems. In renal homeostasis, a SNP in ZNF446 (rs2033711) shows strong association with uric acid clearance in Hispanic children, with the minor allele linked to increased renal urate excretion and potentially reduced gout risk 2. In cancer biology, ZNF446 functions as a SMAD3 cofactor within a complex with ZNF165 and TRIM27 that modulates TGFβ-dependent transcription, promoting triple-negative breast cancer cell viability 3. In bone metabolism, ZNF446 is downregulated in B cells from postmenopausal women with low bone mineral density, implicating it in an ESR1-MAPK3 network associated with osteoporosis pathogenesis 4. Clinically, ZNF446 represents a potential therapeutic target for modulating uric acid excretion, TNBC progression, and postmenopausal bone loss.